Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 59

1.

A 17-Gene Genomic Prostate Score as a Predictor of Adverse Pathology for Men on Active Surveillance.

Kornberg Z, Cooperberg MR, Cowan JE, Chan JM, Shinohara K, Simko JP, Tenggara I, Carroll PR.

J Urol. 2019 Apr 26:101097JU0000000000000290. doi: 10.1097/JU.0000000000000290. [Epub ahead of print]

PMID:
31026214
2.

Correlation of a Commercial Genomic Risk Classifier with Histological Patterns in Prostate Cancer.

Greenland NY, Zhang L, Cowan JE, Carroll PR, Stohr BA, Simko JP.

J Urol. 2019 Jul;202(1):90-95. doi: 10.1097/JU.0000000000000175. Epub 2019 Jun 7.

PMID:
30810466
3.

First-in-Human Phase I study of CTT1057, a Novel 18F Labeled Imaging Agent with Phosphoramidate Core Targeting Prostate Specific Membrane Antigen in Prostate Cancer.

Behr SC, Aggarwal R, Van Brocklin HF, Flavell RR, Geo K, Small EJ, Blecha J, Jivan S, Hope TA, Simko JP, Kurhanewicz J, Noworolski SM, Korn NJ, De Los Santos R, Cooperberg MR, Carroll PR, Nguyen HG, Greene KL, Langton-Webster B, Berkman CE, Seo Y.

J Nucl Med. 2018 Nov 21. pii: jnumed.118.220715. doi: 10.2967/jnumed.118.220715. [Epub ahead of print]

PMID:
30464040
4.

Diagnostic Accuracy of 68Ga-PSMA-11 PET/MRI Compared with Multiparametric MRI in the Detection of Prostate Cancer.

Hicks RM, Simko JP, Westphalen AC, Nguyen HG, Greene KL, Zhang L, Carroll PR, Hope TA.

Radiology. 2018 Dec;289(3):730-737. doi: 10.1148/radiol.2018180788. Epub 2018 Sep 18.

PMID:
30226456
5.

Targeting CD46 for both adenocarcinoma and neuroendocrine prostate cancer.

Su Y, Liu Y, Behrens CR, Bidlingmaier S, Lee NK, Aggarwal R, Sherbenou DW, Burlingame AL, Hann BC, Simko JP, Premasekharan G, Paris PL, Shuman MA, Seo Y, Small EJ, Liu B.

JCI Insight. 2018 Sep 6;3(17). pii: 121497. doi: 10.1172/jci.insight.121497. eCollection 2018 Sep 6.

6.

The Diverse Genomic Landscape of Clinically Low-risk Prostate Cancer.

Cooperberg MR, Erho N, Chan JM, Feng FY, Fishbane N, Zhao SG, Simko JP, Cowan JE, Lehrer J, Alshalalfa M, Kolisnik T, Chelliserry J, Margrave J, Aranes M, Plessis MD, Buerki C, Tenggara I, Davicioni E, Carroll PR.

Eur Urol. 2018 Oct;74(4):444-452. doi: 10.1016/j.eururo.2018.05.014. Epub 2018 May 28.

PMID:
29853306
7.

Polyoma virus-associated carcinomas of the urologic tract: a clinicopathologic and molecular study.

Sirohi D, Vaske C, Sanborn Z, Smith SC, Don MD, Lindsey KG, Federman S, Vankalakunti M, Koo J, Bose S, Peralta-Venturina M, Ziffle JV, Grenert JP, Miller S, Chiu C, Amin MB, Simko JP, Stohr BA, Luthringer DJ.

Mod Pathol. 2018 Sep;31(9):1429-1441. doi: 10.1038/s41379-018-0065-z. Epub 2018 May 15.

PMID:
29765141
8.

Management of Inverted Papilloma During Holmium Laser Enucleation of the Prostate.

Tzou DT, Cadwell C, Simko JP, Chi T, Stoller ML.

Urology. 2018 Jun;116:e5-e6. doi: 10.1016/j.urology.2018.01.009. Epub 2018 Mar 12.

PMID:
29545053
9.

Expression of the DNA repair gene MLH1 correlates with survival in patients who have resected pancreatic cancer and have received adjuvant chemoradiation: NRG Oncology RTOG Study 9704.

Lawrence YR, Moughan J, Magliocco AM, Klimowicz AC, Regine WF, Mowat RB, DiPetrillo TA, Small W Jr, Simko JP, Golan T, Winter KA, Guha C, Crane CH, Dicker AP.

Cancer. 2018 Feb 1;124(3):491-498. doi: 10.1002/cncr.31058. Epub 2017 Oct 20.

10.

Characterization and stratification of prostate lesions based on comprehensive multiparametric MRI using detailed whole-mount histopathology as a reference standard.

Starobinets O, Simko JP, Kuchinsky K, Kornak J, Carroll PR, Greene KL, Kurhanewicz J, Noworolski SM.

NMR Biomed. 2017 Dec;30(12). doi: 10.1002/nbm.3796. Epub 2017 Sep 29.

PMID:
28961382
11.

Renal NUT carcinoma: a case report.

Sirohi D, Garg K, Simko JP, Grenert JP.

Histopathology. 2018 Feb;72(3):528-530. doi: 10.1111/his.13368. Epub 2017 Nov 7. No abstract available.

PMID:
28837236
12.

Pericytic tumors of the kidney-a clinicopathologic analysis of 17 cases.

Sirohi D, Smith SC, Epstein JI, Balzer BL, Simko JP, Balitzer D, Benhamida J, Kryvenko ON, Gupta NS, Paluru S, da Cunha IW, Leal DN, Williamson SR, de Peralta-Venturina M, Amin MB.

Hum Pathol. 2017 Jun;64:106-117. doi: 10.1016/j.humpath.2017.04.005. Epub 2017 Apr 21.

PMID:
28438616
13.

Tissue Sources for Accurate Measurement of Germline DNA Genotypes in Prostate Cancer Patients Treated With Radical Prostatectomy.

Emami NC, Leong L, Wan E, Van Blarigan EL, Cooperberg MR, Tenggara I, Carroll PR, Chan JM, Witte JS, Simko JP.

Prostate. 2017 Mar;77(4):425-434. doi: 10.1002/pros.23283. Epub 2016 Nov 30.

14.

Systemic GM-CSF Recruits Effector T Cells into the Tumor Microenvironment in Localized Prostate Cancer.

Wei XX, Chan S, Kwek S, Lewis J, Dao V, Zhang L, Cooperberg MR, Ryan CJ, Lin AM, Friedlander TW, Rini B, Kane C, Simko JP, Carroll PR, Small EJ, Fong L.

Cancer Immunol Res. 2016 Nov;4(11):948-958. Epub 2016 Sep 29.

15.

18F Fluorocholine Dynamic Time-of-Flight PET/MR Imaging in Patients with Newly Diagnosed Intermediate- to High-Risk Prostate Cancer: Initial Clinical-Pathologic Comparisons.

Choi JY, Yang J, Noworolski SM, Behr S, Chang AJ, Simko JP, Nguyen HG, Carroll PR, Kurhanewicz J, Seo Y.

Radiology. 2017 Feb;282(2):429-436. doi: 10.1148/radiol.2016160220. Epub 2016 Aug 11.

16.

Prostate cancer with a pseudocapsule at MR imaging: a marker of high grade and stage disease?

Bonde AA, Korngold EK, Foster BR, Westphalen AC, Pettersson DR, Troxell ML, Simko JP, Coakley FV.

Clin Imaging. 2016 May-Jun;40(3):365-9. doi: 10.1016/j.clinimag.2015.12.015. Epub 2016 Jan 21.

17.

Application of a Clinical Whole-Transcriptome Assay for Staging and Prognosis of Prostate Cancer Diagnosed in Needle Core Biopsy Specimens.

Knudsen BS, Kim HL, Erho N, Shin H, Alshalalfa M, Lam LLC, Tenggara I, Chadwich K, Van Der Kwast T, Fleshner N, Davicioni E, Carroll PR, Cooperberg MR, Chan JM, Simko JP.

J Mol Diagn. 2016 May;18(3):395-406. doi: 10.1016/j.jmoldx.2015.12.006. Epub 2016 Mar 3.

18.

Mutational Landscape of Aggressive Prostate Tumors in African American Men.

Lindquist KJ, Paris PL, Hoffmann TJ, Cardin NJ, Kazma R, Mefford JA, Simko JP, Ngo V, Chen Y, Levin AM, Chitale D, Helfand BT, Catalona WJ, Rybicki BA, Witte JS.

Cancer Res. 2016 Apr 1;76(7):1860-8. doi: 10.1158/0008-5472.CAN-15-1787. Epub 2016 Feb 26.

19.

Patient-specific Meta-analysis of 2 Clinical Validation Studies to Predict Pathologic Outcomes in Prostate Cancer Using the 17-Gene Genomic Prostate Score.

Brand TC, Zhang N, Crager MR, Maddala T, Dee A, Sesterhenn IA, Simko JP, Cooperberg MR, Srivastava S, Rosner IL, Chan JM, Febbo PG, Carroll PR, Cullen J, Lawrence HJ.

Urology. 2016 Mar;89:69-75. doi: 10.1016/j.urology.2015.12.008. Epub 2015 Dec 23.

20.

Patterns of Local Failure following Radiation Therapy for Prostate Cancer.

Jalloh M, Leapman MS, Cowan JE, Shinohara K, Greene KL, Roach M 3rd, Chang AJ, Chan JM, Simko JP, Carroll PR.

J Urol. 2015 Oct;194(4):977-82. doi: 10.1016/j.juro.2015.04.111. Epub 2015 May 14.

PMID:
25983194
21.

Somatostatin imaging of neuroendocrine-differentiated prostate cancer.

Hope TA, Aggarwal R, Simko JP, VanBrocklin HF, Ryan CJ.

Clin Nucl Med. 2015 Jun;40(6):540-1. doi: 10.1097/RLU.0000000000000776.

PMID:
25783510
22.

Bladder wall recurrence of prostate cancer after high-dose-rate brachytherapy.

Raleigh DR, Hsu IC, Braunstein S, Chang AJ, Simko JP, Roach M 3rd.

Brachytherapy. 2015 Mar-Apr;14(2):185-8. doi: 10.1016/j.brachy.2014.11.008. Epub 2014 Dec 19.

PMID:
25533416
23.

A patient with cholangiocarcinoma demonstrating pathologic complete response to chemotherapy: exploring the role of neoadjuvant therapy in biliary tract cancer.

Walker EJ, Simko JP, Nakakura EK, Ko AH.

J Gastrointest Oncol. 2014 Dec;5(6):E88-95. doi: 10.3978/j.issn.2078-6891.2014.051.

24.

Extended followup and risk factors for disease reclassification in a large active surveillance cohort for localized prostate cancer.

Welty CJ, Cowan JE, Nguyen H, Shinohara K, Perez N, Greene KL, Chan JM, Meng MV, Simko JP, Cooperberg MR, Carroll PR.

J Urol. 2015 Mar;193(3):807-11. doi: 10.1016/j.juro.2014.09.094. Epub 2014 Sep 28.

25.
26.

Clinical utility of endorectal MRI-guided prostate biopsy: preliminary experience.

Jung AJ, Westphalen AC, Kurhanewicz J, Wang ZJ, Carroll PR, Simko JP, Coakley FV.

J Magn Reson Imaging. 2014 Aug;40(2):314-23. doi: 10.1002/jmri.24383. Epub 2013 Oct 31.

27.

miR-19, miR-345, miR-519c-5p serum levels predict adverse pathology in prostate cancer patients eligible for active surveillance.

Wang SY, Shiboski S, Belair CD, Cooperberg MR, Simko JP, Stoppler H, Cowan J, Carroll PR, Blelloch R.

PLoS One. 2014 Jun 3;9(6):e98597. doi: 10.1371/journal.pone.0098597. eCollection 2014.

28.

A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling.

Klein EA, Cooperberg MR, Magi-Galluzzi C, Simko JP, Falzarano SM, Maddala T, Chan JM, Li J, Cowan JE, Tsiatis AC, Cherbavaz DB, Pelham RJ, Tenggara-Hunter I, Baehner FL, Knezevic D, Febbo PG, Shak S, Kattan MW, Lee M, Carroll PR.

Eur Urol. 2014 Sep;66(3):550-60. doi: 10.1016/j.eururo.2014.05.004. Epub 2014 May 16.

29.

Role of endorectal MR imaging and MR spectroscopic imaging in defining treatable intraprostatic tumor foci in prostate cancer: quantitative analysis of imaging contour compared to whole-mount histopathology.

Anwar M, Westphalen AC, Jung AJ, Noworolski SM, Simko JP, Kurhanewicz J, Roach M 3rd, Carroll PR, Coakley FV.

Radiother Oncol. 2014 Feb;110(2):303-8. doi: 10.1016/j.radonc.2013.12.003. Epub 2014 Jan 17.

30.

Successful whole-exome sequencing from a prostate cancer bone metastasis biopsy.

Van Allen EM, Foye A, Wagle N, Kim W, Carter SL, McKenna A, Simko JP, Garraway LA, Febbo PG.

Prostate Cancer Prostatic Dis. 2014 Mar;17(1):23-7. doi: 10.1038/pcan.2013.37. Epub 2013 Dec 24.

31.

Semiautomatic registration of digital histopathology images to in vivo MR images in molded and unmolded prostates.

Starobinets O, Guo R, Simko JP, Kuchinsky K, Kurhanewicz J, Carroll PR, Greene KL, Noworolski SM.

J Magn Reson Imaging. 2014 May;39(5):1223-9. doi: 10.1002/jmri.24287. Epub 2013 Oct 17.

32.

Editorial comment.

Simko JP.

J Urol. 2013 Dec;190(6):2066-7. doi: 10.1016/j.juro.2013.06.120. Epub 2013 Sep 16. No abstract available.

PMID:
24050907
33.

Pulmonary coccidiomycosis masquerading as refractory metastatic Ewing sarcoma.

Stieglitz E, Hsiang MS, Simko JP, Hirose S, Goldsby RE.

J Pediatr Hematol Oncol. 2014 Jan;36(1):e57-60. doi: 10.1097/MPH.0b013e318286d4fd.

PMID:
23588326
34.

Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors.

Ducker GS, Atreya CE, Simko JP, Hom YK, Matli MR, Benes CH, Hann B, Nakakura EK, Bergsland EK, Donner DB, Settleman J, Shokat KM, Warren RS.

Oncogene. 2014 Mar 20;33(12):1590-600. doi: 10.1038/onc.2013.92. Epub 2013 Apr 1.

35.

Benign prostate glandular tissue at radical prostatectomy surgical margins.

Odisho AY, Washington SL 3rd, Meng MV, Cowan JE, Simko JP, Carroll PR.

Urology. 2013 Jul;82(1):154-9. doi: 10.1016/j.urology.2012.12.063. Epub 2013 Mar 21.

36.

Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort.

Cooperberg MR, Simko JP, Cowan JE, Reid JE, Djalilvand A, Bhatnagar S, Gutin A, Lanchbury JS, Swanson GP, Stone S, Carroll PR.

J Clin Oncol. 2013 Apr 10;31(11):1428-34. doi: 10.1200/JCO.2012.46.4396. Epub 2013 Mar 4.

37.

Diversity of antigen-specific responses induced in vivo with CTLA-4 blockade in prostate cancer patients.

Kwek SS, Dao V, Roy R, Hou Y, Alajajian D, Simko JP, Small EJ, Fong L.

J Immunol. 2012 Oct 1;189(7):3759-66. Epub 2012 Sep 5.

38.

Do adenocarcinomas of the prostate with Gleason score (GS) ≤6 have the potential to metastasize to lymph nodes?

Ross HM, Kryvenko ON, Cowan JE, Simko JP, Wheeler TM, Epstein JI.

Am J Surg Pathol. 2012 Sep;36(9):1346-52. doi: 10.1097/PAS.0b013e3182556dcd.

39.

Metastatic melanoma with striking adenocarcinomatous differentiation illustrating phenotypic plasticity in melanoma.

Jalas JR, Vemula S, Bezrookove V, Leboit PE, Simko JP, Bastian BC.

Am J Surg Pathol. 2011 Sep;35(9):1413-8. doi: 10.1097/PAS.0b013e31822280d8.

40.

Factors associated with downgrading in patients with high grade prostate cancer.

Whitson JM, Porten SP, Cowan JE, Simko JP, Cooperberg MR, Carroll PR.

Urol Oncol. 2013 May;31(4):442-7. doi: 10.1016/j.urolonc.2011.02.010. Epub 2011 Apr 8.

41.

The relationship between prostate specific antigen change and biopsy progression in patients on active surveillance for prostate cancer.

Whitson JM, Porten SP, Hilton JF, Cowan JE, Perez N, Cooperberg MR, Greene KL, Meng MV, Simko JP, Shinohara K, Carroll PR.

J Urol. 2011 May;185(5):1656-60. doi: 10.1016/j.juro.2010.12.042. Epub 2011 Mar 21.

PMID:
21419438
42.

Emergent orthotopic liver transplantation for hemorrhage from a giant cavernous hepatic hemangioma: case report and review.

Vagefi PA, Klein I, Gelb B, Hameed B, Moff SL, Simko JP, Fix OK, Eilers H, Feiner JR, Ascher NL, Freise CE, Bass NM.

J Gastrointest Surg. 2011 Jan;15(1):209-14. doi: 10.1007/s11605-010-1248-1. Epub 2010 Jun 12.

43.

Metabolic, pathologic, and genetic analysis of prostate tissues: quantitative evaluation of histopathologic and mRNA integrity after HR-MAS spectroscopy.

Santos CF, Kurhanewicz J, Tabatabai ZL, Simko JP, Keshari KR, Gbegnon A, Santos RD, Federman S, Shinohara K, Carroll PR, Haqq CM, Swanson MG.

NMR Biomed. 2010 May;23(4):391-8. doi: 10.1002/nbm.1474. Epub 2009 Dec 23.

44.

Mucinous adenocarcinoma of the prostate: MRI and MR spectroscopy features.

Westphalen AC, Coakley FV, Kurhanewicz J, Reed G, Wang ZJ, Simko JP.

AJR Am J Roentgenol. 2009 Sep;193(3):W238-43. doi: 10.2214/AJR.08.1495.

45.

An aberrant prostate antigen-specific immune response causes prostatitis in mice and is associated with chronic prostatitis in humans.

Hou Y, DeVoss J, Dao V, Kwek S, Simko JP, McNeel DG, Anderson MS, Fong L.

J Clin Invest. 2009 Jul;119(7):2031-41. doi: 10.1172/JCI38332.

46.

PI(3) kinase is associated with a mechanism of immunoresistance in breast and prostate cancer.

Crane CA, Panner A, Murray JC, Wilson SP, Xu H, Chen L, Simko JP, Waldman FM, Pieper RO, Parsa AT.

Oncogene. 2009 Jan 15;28(2):306-12. doi: 10.1038/onc.2008.384. Epub 2008 Oct 13.

47.

Evaluation of lactate and alanine as metabolic biomarkers of prostate cancer using 1H HR-MAS spectroscopy of biopsy tissues.

Tessem MB, Swanson MG, Keshari KR, Albers MJ, Joun D, Tabatabai ZL, Simko JP, Shinohara K, Nelson SJ, Vigneron DB, Gribbestad IS, Kurhanewicz J.

Magn Reson Med. 2008 Sep;60(3):510-6. doi: 10.1002/mrm.21694.

48.

Quantification of choline- and ethanolamine-containing metabolites in human prostate tissues using 1H HR-MAS total correlation spectroscopy.

Swanson MG, Keshari KR, Tabatabai ZL, Simko JP, Shinohara K, Carroll PR, Zektzer AS, Kurhanewicz J.

Magn Reson Med. 2008 Jul;60(1):33-40. doi: 10.1002/mrm.21647.

49.

Peripheral zone prostate cancer: accuracy of different interpretative approaches with MR and MR spectroscopic imaging.

Westphalen AC, Coakley FV, Qayyum A, Swanson M, Simko JP, Lu Y, Zhao S, Carroll PR, Yeh BM, Kurhanewicz J.

Radiology. 2008 Jan;246(1):177-84. Epub 2007 Nov 16.

PMID:
18024434
50.

Recombinant full-length human IgG1s targeting hormone-refractory prostate cancer.

Liu B, Conrad F, Roth A, Drummond DC, Simko JP, Marks JD.

J Mol Med (Berl). 2007 Oct;85(10):1113-23. Epub 2007 Jun 7.

PMID:
17554518

Supplemental Content

Loading ...
Support Center